Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib

Article Details

Authors
Novin Nezamololama, BSc, MSc, Keira Fieldhouse, BSc, Kristy Metzger, BSc, Melinda Gooderham, MD, MSc, FRCPC

Article Type
Review

DOI
10.7573/dic.2020-8-5

Related Articles

Article Page

Abstract

The Janus kinases (JAK) are a group of molecules, composed of JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), which are key components within the JAK–signal transducers and activators of transcription pathway, where cytokine receptor signaling takes place. These molecules play a foundational role in the underlying pathogenesis of multiple immune-related conditions such as atopic dermatitis (AD), rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and others. Thus far, JAK inhibitors for inflammatory conditions have only been marketed for the treatment of rheumatoid arthritis and psoriatic arthritis, but ongoing phase II and phase III clinical trials for other immune-mediated diseases, such as AD, have also shown promising results. This review summarizes the clinical data available from various trials and reports on the safety and efficacy of abrocitinib, baricitinib, and upadacitinib, the three oral systemic JAK inhibitors used in the treatment of AD. The safety and efficacy of JAK inhibitors for the treatment of AD are emerging in the literature. It is important that dermatologists are aware of any potential adverse events or risks associated with the use of JAK inhibitors in order to promote a higher standard of treatment and quality of living.

Keywords: abrocitinib, atopic dermatitis, baricitinib, eczema, JAK1, JAK2, JAK inhibitors, upadacitinib.

Citation: Nezamololama N, Fieldhouse K, Metzger K, Gooderham M. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib. Drugs in Context 2020; 9: 2020-8-5. DOI: 10.7573/dic.2020-8-5

Contributions: All named authors have contributed to the preparation of this article and have approved this version of the article to be published.

Disclosure and potential conflicts of interest: KF, KM, and NN declare no conflicts of interest. MG has been an investigator, speaker, consultant or advisory board member for AbbVie, Amgen, Akros, Arcutis, Boehringer Ingelheim, BMS, Celgene, Dermira, Dermavant, Galderma, GSK, Eli Lilly, Incyte, Janssen, Kyowa Kirin, Leo Pharma, Medimmune, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, UCB, and Valeant/Bausch. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2020/10/dic.2020-8-5-COI.pdf

Acknowledgements: None.

Funding declaration: There was no funding associated with the preparation of this article.

Copyright: Copyright © 2020 Nezamololama N, Fieldhouse K, Metzger K, Gooderham M. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2020 Nezamololama N, Fieldhouse K, Metzger K, Gooderham M. https://doi.org/10.7573/dic.2020-8-5. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/emerging-systemic-jak-inhibitors-in-the-treatment-of-atopic-dermatitis:-a-review-of-abrocitinib,-baricitinib,-and-upadacitinib

Correspondence: Melinda J Gooderham, Skin Centre for Dermatology, 775 Monaghan Road South, Peterborough, ON K9J 5K2, Canada. mgooderham@centrefordermatology.com

Provenance: Invited; externally peer reviewed.

Submitted: 9 August 2020; Peer review comments to author: 9 September 2020; Revised manuscript received: 2 October 2020; Accepted: 5 October 2020; Publication date: 16 November 2020.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editorial office editorial@drugsincontext.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF